Scarica l'app Stockscreener
24.92
1.52%
0.3066
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Immunovant Inc Borsa (IMVT) Ultime notizie
IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - bitget.com
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance
Immunovant falls on late-stage trial setback for TED therapy - MSN
Immunovant Inc stock: Why biotech investors are watching this closely now - AD HOC NEWS
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT - MarketBeat
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock - MarketBeat
Immunovant (IMVT) CEO Venker sells $342,854 in shares By Investing.com - Investing.com India
Immunovant (IMVT) CEO Venker sells $342,854 in shares - Investing.com
Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock - Stock Titan
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
IMVT Should I Buy - intellectia.ai
Truist reiterates Hold on Immunovant stock after trial failure By Investing.com - Investing.com India
Immunovant's treatment for eye disease fails in late-stage trials - Reuters
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data UpdateSlideshow - Seeking Alpha
IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy - TradingView
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance
Leerink cuts Immunovant stock price target on failed TED trial By Investing.com - Investing.com Australia
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - BioPharma Dive
Leerink cuts Immunovant stock price target on failed TED trial - Investing.com
Oppenheimer maintains Immunovant stock rating on next-gen drug focus By Investing.com - Investing.com India
Oppenheimer maintains Immunovant stock rating on next-gen drug focus - Investing.com UK
IMVT: Batoclimab missed its Phase 3 endpoint in thyroid eye disease; focus shifts to IMVT-1402 - tradingview.com
Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights
Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials By Investing.com - Investing.com Canada
Hennion & Walsh Asset Management Inc. Makes New Investment in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - manilatimes.net
Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials - Investing.com
Two late-stage thyroid eye disease trials miss for Immunovant - Stock Titan
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN
Sjögren’s Syndrome Market Poised for Significant Expansion Through 2034, Driven by Advancing Pipeline Therapies and Rising Disease Burden | DelveInsight Analysis Featuring Astellas Pharma, Immunovant - Barchart
Responsive Playbooks and the IMVT Inflection - Stock Traders Daily
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - AOL.com
EPS Watch: Does PCOR have consistent dividend growthExit Point & Fast Moving Stock Watchlists - baoquankhu1.vn
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com India
Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move - TipRanks
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - MarketBeat
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com - za.investing.com
Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan
2.27%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):